Peptide library / Bones & muscles / Palopegteriparatide
Palopegteriparatide
A long-acting prodrug of parathyroid hormone given once daily for hypoparathyroidism.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Hypoparathyroidism in adultsFDA approved
How it is thought to work
The active hormone is attached to a carrier that releases it slowly, producing steadier levels over 24 hours.
What the evidence shows
In the PaTHway trial, most participants reached normal calcium without conventional calcium and active vitamin D.
Safety and unknowns
Injection site reactions, headache and low or high calcium.
Regulatory status
FDA-approved as Yorvipath in 2024.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Bones & muscles
Parathyroid hormone 1-84
FDA-approvedThe full-length parathyroid hormone, once used for hypoparathyroidism and now withdrawn.
PEG-MGF
Wellness and performanceA long-acting version of mechano growth factor, studied only in animals.
Osteogenic growth peptide
Wellness and performanceA 14 amino acid peptide found in blood that stimulates bone formation in animals.
General information, not medical advice. Do not buy or inject unregulated peptides.